DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Blocking the complement system is a promising strategy to impede the progression of metabolic dysfunction–associated steatotic liver disease (MASLD). However, the interplay between complement and MASLD remains to be elucidated. This comprehensive approach aimed to investigate the potential association between complement dysregulation and the histological severity of MASLD. Methods: Liver biopsy specimens were procured from a cohort comprising 106 Korean individuals, which included 31 controls, 17 with isolated steatosis, and 58 with metabolic dysfunction–associated steatohepatitis (MASH). Utilizing the Infinium Methylation EPIC array, thorough analysis of methylation alterations in 61 complement genes was conducted. The expression and methylation of nine complement genes in a murine MASH model were examined using quantitative RT-PCR and pyrosequencing. Results: Methylome and transcriptome analyses of liver biopsies revealed significant (P<0.05) hypermethylation and downregulation of C1R, C1S, C3, C6, C4BPA, and SERPING1, as well as hypomethylation (P<0.0005) and upregulation (P<0.05) of C5AR1, C7, and CD59, in association with the histological severity of MASLD. Furthermore, DNA methylation and the relative expression of nine complement genes in a MASH diet mouse model aligned with human data. Conclusions: Our research provides compelling evidence that epigenetic alterations in complement genes correlate with MASLD severity, offering valuable insights into the mechanisms driving MASLD progression, and suggests that inhibiting the function of certain complement proteins may be a promising strategy for managing MASLD.
Abstract
Background/Aims: Blocking the complement system is a promising strategy to impede the progression of metabolic dysfunction–associated steatotic liver disease (MASLD). However, the interplay between complement and MASLD remains to be elucidated. This comprehensive approach aimed to investigate the potential association between complement dysregulation and the histological severity of MASLD. Methods: Liver biopsy specimens were procured from a cohort comprising 106 Korean individuals, which included 31 controls, 17 with isolated steatosis, and 58 with metabolic dysfunction–associated steatohepatitis (MASH). Utilizing the Infinium Methylation EPIC array, thorough analysis of methylation alterations in 61 complement genes was conducted. The expression and methylation of nine complement genes in a murine MASH model were examined using quantitative RT-PCR and pyrosequencing. Results: Methylome and transcriptome analyses of liver biopsies revealed significant (P<0.05) hypermethylation and downregulation of C1R, C1S, C3, C6, C4BPA, and SERPING1, as well as hypomethylation (P<0.0005) and upregulation (P<0.05) of C5AR1, C7, and CD59, in association with the histological severity of MASLD. Furthermore, DNA methylation and the relative expression of nine complement genes in a MASH diet mouse model aligned with human data. Conclusions: Our research provides compelling evidence that epigenetic alterations in complement genes correlate with MASLD severity, offering valuable insights into the mechanisms driving MASLD progression, and suggests that inhibiting the function of certain complement proteins may be a promising strategy for managing MASLD.
참고문헌 (52)
- Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
- Le MH, "Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach", Clin Mol Hepatol, 28, pp.841~850 (2022)
- Lim HJ, "EZH2 as a potential target for NAFLD therapy", Int J Mol Sci, 21, pp.8617~ (2020)
- Johnson ND, "Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD", Clin Epigenetics, 13, pp.152~ (2021)
- Murphy SK, "Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease", Gastroenterology, 145, pp.1076~1087 (2013)
- Ricklin D, "Complement : a key system for immune surveillance and homeostasis", Nat Immunol, 11, pp.785~797 (2010)
- Schraufstatter IU, "Complement activation in the context of stem cells and tissue repair", World J Stem Cells, 7, pp.1090~1108 (2015)
- Zhou Y, "Roles of the complement system in alcohol-induced liver disease", Clin Mol Hepatol, 26, pp.677~685 (2020)
- Ricklin D, "Complement in disease : a defence system turning offensive", Nat Rev Nephrol, 12, pp.383~401 (2016)
- Guo Z, "The role of complement in nonalcoholic fatty liver disease", Front Immunol, 13, pp.1017467~ (2022)
- Zhao J, "Association of complement components with the risk and severity of NAFLD : a systematic review and meta-analysis", Front Immunol, 13, pp.1054159~ (2022)
- Lung T, "The complement system in liver diseases : evidencebased approach and therapeutic options", J Transl Autoimmun, 2, pp.100017~ (2019)
- Bavia L, "The complement component C5 promotes liver steatosis and inflammation in murine non-alcoholic liver disease model", Immunol Lett, 177, pp.53~61 (2016)
- Nguyen VD, "From complement to complosome in non-alcoholic fatty liver disease : when location matters", Liver Int, 44, pp.316~329 (2024)
- Han J, "Complement component C3 : a novel biomarker participating in the pathogenesis of non-alcoholic fatty liver disease", Front Med(Lausanne), 8, pp.653293~ (2021)
- Yoo T, "Diseasespecific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease", J Hepatol, 75, pp.514~523 (2021)
- Koo BK, "Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 33, pp.1277~1285 (2018)
- Brunt EM, "Nonalcoholic fatty liver disease(NAFLD)activity score and the histopathologic diagnosis in NAFLD : distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)
- Bedossa P, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients", Hepatology, 56, pp.1751~1759 (2012)
- Govaere O, "Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis", Sci Transl Med, 12, pp.eaba4448~ (2020)
- Gribben C, "Acquisition of epithelial plasticity in human chronic liver disease", Nature, 630, pp.166~173 (2024)
- Halpern KB, "Paired-cell sequencing enables spatial gene expression mapping of liver endothelial cells", Nat Biotechnol, 36, pp.962~970 (2018)
- MacParland SA, "Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations", Nat Commun, 9, pp.4383~ (2018)
- Aizarani N, "A human liver cell atlas reveals heterogeneity and epithelial progenitors", Nature, 572, pp.199~204 (2019)
- Guilliams M, "Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches", Cell, 185, pp.379~396 (2022)
- Roadmap Epigenomics Consortium, "Integrative analysis of 111reference human epigenomes", Nature, 518, pp.317~330 (2015)
- Kendall TJ, "An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease", Nat Med, 29, pp.2939~2953 (2023)
- Paris J, "Liver zonation, revisited", Hepatology, 76, pp.1219~1230 (2022)
- Ben-Moshe S, "Spatial sorting enables comprehensive characterization of liver zonation", Nat Metab, 1, pp.899~911 (2019)
- Jones PA, "Cellular differentiation, cytidine analogs and DNA methylation", Cell, 20, pp.85~93 (1980)
- Shi Y, "Proteincentric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets", Clin Mol Hepatol, 30, pp.80~97 (2024)
- Lubbers R, "Production of complement components by cells of the immune system", Clin Exp Immunol, 188, pp.183~194 (2017)
- Markiewski MM, "C3a and C3b activation products of the third component of complement(C3)are critical for normal liver recovery after toxic injury", J Immunol, 173, pp.747~754 (2004)
- Mastellos D, "A novel role of complement : mice deficient in the fifth component of complement(C5)exhibit impaired liver regeneration", J Immunol, 166, pp.2479~2486 (2001)
- Yesilova Z, "Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance", Am J Gastroenterol, 100, pp.842~849 (2005)
- Engström G, "Complement C3 is a risk factor for the development of diabetes : a population-based cohort study", Diabetes, 54, pp.570~575 (2005)
- Naughton MA, "Extrahepatic secreted complement C3contributes to circulating C3 levels in humans", J Immunol, 156, pp.3051~3056 (1996)
- Wlazlo N, "Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3 : the CODAM study", Metabolism, 61, pp.1787~1796 (2012)
- Segers FM, "Complement alternative pathway activation in human nonalcoholic steatohepatitis", PLoS One, 9, pp.e110053~ (2014)
- Li Y, "Intracellular C3prevents hepatic steatosis by promoting autophagy and verylow-density lipoprotein secretion", FASEB J, 35, pp.e22037~ (2021)
- Krenkel O, "Liver macrophages in tissue homeostasis and disease", Nat Rev Immunol, 17, pp.306~321 (2017)
- Robinson MW, "Liver immunology and its role in inflammation and homeostasis", Cell Mol Immunol, 13, pp.267~276 (2016)
- Phieler J, "The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance", J Immunol, 191, pp.4367~4374 (2013)
- Castellano G, "Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4", βcatenin signaling after ischemia, Aging(Albany NY), pp.2019, 11[DOI]
- Bell LN, "Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease", Hepatology, 51, pp.111~120 (2010)
- Hou W, "Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant", advanced fibrosis in patients with nonalcoholic fatty liver disease, 2020, pp.40, BSR20190395~
- Wang Z, "Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes", Brain Behav Immun, 65, pp.173~182 (2017)
- Chalasani N, "Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease", J Hepatol, 48, pp.829~834 (2008)
- Mastellos DC, "Clinical promise of nextgeneration complement therapeutics", Nat Rev Drug Discov, 18, pp.707~729 (2019)
- Jayne DRW, "Avacopan for the treatment of ANCA-associated vasculitis. Reply", N Engl J Med, 384, pp.e81~ (2021)
- Wijnsma KL, "Eculizumab in atypical hemolytic uremic syndrome : strategies toward restrictive use", Pediatr Nephrol, 34, pp.2261~2277 (2019)
- Lim J, "C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling", FASEB J, 27, pp.822~831 (2013)